Ibritumomab tiuxetan
- Generic Name
- Ibritumomab tiuxetan
- Brand Names
- Zevalin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 206181-63-7
- Unique Ingredient Identifier
- 4Q52C550XK
- Background
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
- Indication
For treatment of non-Hodgkin's lymphoma
- Associated Conditions
- Follicular Non-Hodgkin's Lymphoma, Follicular Non-Hodgkin's Lymphoma Refractory, Relapsed follicular B-cell non-Hodgkin's lymphoma
- Associated Therapies
- -
Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec
WuXi AppTec’s Dr Dave Madge predicts peptide-based radiotherapeutics could surpass antibody-based counterparts due to advantages like tissue penetration and low toxicity. Despite only two antibody-based radiopharmaceuticals being FDA-approved, the radiopharmaceutical space has seen significant deals, with theranostic radiopharmaceuticals combining diagnostics and therapy gaining traction. WuXi’s expansion in peptide manufacturing aims to meet global demand, but potential restrictions from the US BIOSECURE Act pose a challenge.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath